Grifols S.A.
GRFS evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $5.09B
- Lead Asset:
- sodium chloride 0.9% in plastic container (Approved)
What it means
What to watch
Prepared research question
What matters most for GRFS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRFS
Grifols S.A. is a global plasma-derived therapies company with a vertically integrated model, focused on immunoglobulin (IG) and Alpha-1 franchises, pipeline execution, and deleveraging, reporting 2025 revenue of €1,549M and a net loss of €-1,148M as of 2025-12-31 [sec].
Key risk: Net loss and accumulated deficit
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$5.09B
Cash Runway
—
Next Catalyst
—
Tracking 1 pipeline candidate · 1 FDA decision for Grifols S.A..
Grifols S.A. is a global plasma-derived therapies company with a vertically integrated model, focused on immunoglobulin (IG) and Alpha-1 franchises, pipeline execution, and deleveraging, reporting 2025 revenue of €1,549M and a net loss of €-1,148M as of 2025-12-31 [sec].
- Revenue of €1,549M and net loss of €-1,148M for fiscal year 2025 as of 2025-12-31 [sec].
- Cash and cash equivalents of €1,093M as of 2025-12-31 [sec].
- Biopharma revenue grew +8.2% cc in H1'25 vs H1'24, driven by IG and Alpha-1 [sec · filed 2025-07-30].
- Phase III top-line results for Prolastin-C in AATD expected by H2'26 [sec · filed 2025-11-04].
- Fibrinogen launch in Europe on track for Q4'25 and US BLA with PDUFA date end of December [sec · filed 2025-11-04].
What works
- Vertically integrated plasma supply chain in the US and Europe provides resilience and optionality [sec · filed 2025-11-04].
- IG growth performance more than offset IRA impact in 2025, with double-digit growth ahead of market [sec · filed 2026-02-26].
- Strong re-rating progress across all three credit rating agencies, reflecting improved financial profile [sec · filed 2026-02-26].
- Pipeline execution advancing with key milestones: Fibrinogen EU launch Q4'25, US BLA with PDUFA end of December, and Phase III Alpha-1 readout H2'26 [sec · filed 2025-11-04].
What to weigh
- Net loss of €-1,148M for FY 2025 as of 2025-12-31, indicating significant bottom-line pressure [sec].
- Accumulated deficit of €-1,148M as of 2025-12-31, reflecting historical financial strain [sec].
- Complex macroeconomic and geopolitical environment with persistent international tensions and financial episodes [sec · filed 2026-02-26].
- IRA impact on margins, though partially offset by IG growth, remains a structural headwind [sec · filed 2026-02-26].
From the filings
Quoted directly from source documents.
Phase III Alpha-1 readout timeline
“Expect phase III top-line results by H2'26”
SEC filings · November 4, 2025
Fibrinogen US BLA PDUFA date
“On track with BLA for CFD with PDUFA date end of December”
SEC filings · November 4, 2025
IG growth offset IRA impact
“Ig growth performance, more than offsets IRA impact in 2025”
SEC filings · February 26, 2026
Risks & what to watch (4)›
Key risks
- Net loss and accumulated deficit — Net loss of €-1,148M and accumulated deficit of €-1,148M as of 2025-12-31 [sec].
- IRA margin pressure — IRA impact on margins, though partially offset by IG growth, remains a structural headwind [sec · filed 2026-02-26].
- Geopolitical and financial instability — Complex macroeconomic and geopolitical environment with persistent international tensions [sec · filed 2026-02-26].
- Bond refinancing exposure — 2027 bond refinancing scheduled for Q4'26 or earlier, subject to market conditions [sec · filed 2026-02-26].
What to watch
- Phase III top-line results for Prolastin-C in AATD expected by H2'26 [sec · filed 2025-11-04].
- Fibrinogen US BLA decision with PDUFA date end of December [sec · filed 2025-11-04].
- 2027 bond refinancing execution in Q4'26 or earlier [sec · filed 2026-02-26].
- Continued IG market share recovery and SCIG penetration with Xembify [sec · filed 2025-11-04].
Sources: SEC filings · Generated October 2, 2026 · How we verify sources →
Run Grifols S.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Grifols S.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
183
Total value held
$1.14B
| Holder | Shares | Value |
|---|---|---|
| brandes investment partners, lp | 36,333,714 | $291.4M |
| capital world investors | 22,924,990 | $183.9M |
| permian investment partners, lp | 19,354,679 | $155.2M |
| black creek investment management inc. | 8,386,452 | $67.3M |
| millennium management llc | 5,005,532 | $40.1M |
| bank of america corp /de/ | 4,327,413 | $34.7M |
| janus henderson group plc | 3,290,089 | $26.4M |
| ubs group ag | 3,156,653 | $25.3M |
| armistice capital, llc | 2,988,000 | $24.0M |
| morgan stanley | 2,857,956 | $22.9M |
Showing top 10 of 183 institutional holders of Grifols S.A.. Open the full 13F history after sign-in.
Frequently asked questions
What is the AI investment thesis for Grifols S.A.?
Grifols S.A. is a global plasma-derived therapies company with a vertically integrated model, focused on immunoglobulin (IG) and Alpha-1 franchises, pipeline execution, and deleveraging, reporting 2025 revenue of €1,549M and a net loss of €-1,148M as of 2025-12-31 [sec].
What is Grifols S.A.'s lead drug candidate?
Grifols S.A.'s most advanced tracked candidate is sodium chloride 0.9% in plastic container (Approved).
Who is the CEO of Grifols S.A.?
Mr. Jose Ignacio Abia Buenache is the chief executive officer of Grifols S.A. (GRFS).
Where is Grifols S.A. headquartered?
Grifols S.A. (GRFS) is headquartered in Barcelona, Spain.
What therapeutic areas does Grifols S.A. focus on?
Grifols S.A. develops therapies across Oncology, Ophthalmology, Respiratory, Dermatology, Hematology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.